RxSight, Inc.

Hello, everyone. Thank you for standing by. My name is Will, and I will be your operator for today. At this time, I would like to welcome each and every one of you to the RxSight 3rd Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star followed by the number one on a telephone keypad. I will now turn the call over to Mr. Oliver Moravcevic, Vice President of Investor Relations. Please go ahead.

Thank you, Operator. Presenting today are RxSight President and Chief Executive Officer Dr. Ron Kurtz and Chief Financial Officer Shally Toonan. Earlier today, RxSight released its financial results for the three months ending September 30, 2025, and updated its full-year guidance. A copy of the press release is available on the company's website. Before we begin, I would like to inform you that comments and responses to questions during today's call reflect management's views as of today, November 5, 2025, and will include forward-looking and opinion statements, including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain long-gap financial measures. Disclosures regarding non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our investor relations website. With that, I will turn the call over to our President and Chief Executive Officer, Dr. Ron Kurtz. Ron?

Good afternoon, everyone, and thank you for joining us. During the third quarter, we've made meaningful progress strengthening our commercial execution in the U.S., while laying the groundwork for our broader global growth. We aligned our clinical and sales teams to create a more integrated approach for customers, enabling us to improve training and engagement, an approach that we continue to view as the most consistent driver for both future LAL and LDD growth. We launched the first of several new practice development and clinical engagement programs including the MasterClass and Elevate programs that are designed to share learnings from over 250,000 LAL cases, helping practices optimize LAL workflow, enhance clinical confidence, and accelerate their path to becoming experts in postoperative adjustability. During the quarter, more than 2,000 ophthalmologists implanted the light-adjustable lens, representing roughly one-fifth of the estimated total number of U.S. cataract surgeons. With approximately 1,100 LDDs in the field, we have ample opportunities to expand access to the LAL to more patients, and we continue to see healthy demand and growing interest from new doctors and practices. Our focus is on strategically expanding our base of LDDs and implanting surgeons, while positioning our customers for success and sustained growth. Internationally, we're making steady progress on our deliberate and focused rollouts in Asia and Europe, with key regulatory infrastructure and commercial initiatives underway to support our multi-year expansion across priority global markets. During the third quarter, we also added an executive vice president of international to lead this expansion. We recognize there's more work ahead, but the engagement we're seeing across our customer base gives us confidence that we are building a strong foundation for the future. With that, I'll hand it over to Shelly, who will review our third quarter financials and updated guidance.